JAK-independent constitutive signaling will derive a competitive advantage in the setting of potent JAK2 inhibition. A combined application of imatinib and ruxolitinib is unlikely to solve that issue as JAK2 deficiency fails to enhance sensitivity to imatinib in BCR-ABL þ LSKs. However, we hypothesize that in some cases, JAK2 inhibitormediated effects on stem cells might be advantageous; for example, as an adjunct to stem cell transplantation. However, in summary our data support the notion that JAK2 has a critical role in normal hematopoiesis, and current and future therapeutic approaches aimed at targeting JAK2 need to consider effects on stem cell function and the relative inhibitory effects on normal and malignant cells, which might limit, or even abrogate, therapeutic efficacy.
One approach to improve risk prognostication in patients with multiple myeloma (MM) is to use new technologies to stratify patients based on distinct outcomes. 1 Outcome prediction for most patients is based on the International Staging System (ISS) and the presence or absence of specific fluorescent in-situ hybridization abnormalities. Additional biomarkers are necessary to improve precision, and there is evidence that small non-coding RNAs, microRNAs (miRNAs), are involved in MM pathogenesis, [2] [3] [4] but the predictive role of circulating miRNAs remains to be fully evaluated.
Accepted article preview online 12 May 2014; advance online publication, 6 June 2014 Letters to the Editor To address this question, we measured serum miRNA levels of a large cohort of newly diagnosed MM patients who were uniformly treated and followed, correlating miRNA levels with clinical outcome to test their prognostic impact in a multivariate model.
Patients with previously untreated transplant-ineligible MM enrolled on a Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) phase III clinical trial and with material available for analysis (n ¼ 288) were studied for serum levels of miRNAs. 5 Patients received Velcade-Melphalan-Prednisone (VMP) or Velcade-Melphalan-Prednisone-Thalidomide followed by maintenance with Velcade-Thalidomide (VMPT-VT) through the parent clinical trial (NCT#01063179).
RNA was isolated from the serum of 54 randomly selected MM patients, analyzed by NanoString, and only those miRNAs consistently expressed over the background threshold in at least 20% of samples were selected. These miRNAs were measured by quantitative real-time PCR analyses using the 2^-dct methods. 6, 7 In addition, a composite indicator of high-risk genetic features was generated and evaluated in these analyses, which was regarded as positive if the patient had any of the following: del17, t(4;14), t(14;16); otherwise, they were classified as standard risk.
Univariate Cox regression models were used to assess the influence of continuous expression levels for the miRNAs in relation to PFS and OS. We tested the proportional hazards assumption for a Cox regression model fit for each of the covariates. 8 In the presence of non-proportional hazards, weighted estimation in the Cox regression model was used to provide unbiased average hazard ratio estimates. 9 Any miRNA, clinical, and/or molecular covariates that were significant at the Po0.10 level were brought forward for evaluation in the multivariable setting.
To identify circulating miRNAs with potential clinical impact, we analyzed by Nanostring the serum samples of a discovery set of 54 newly diagnosed MM patients randomly selected for analysis from 288 patients enrolled on a randomized phase III study of VMP versus VMPT-VT (Supplementary Figure A1 , Supplementary Information Table A1 ). Out of the 800 miRNAs evaluated, only 25 were detectable (X100 counts) in at least 20% of the patients (Figures 1a and b) . The expression of these miRNAs was then measured in a validation set of 234 patients by quantitative realtime PCR. Of the 25 serum miRNAs (S-miRNAs), only 10 (S-miRs92a, 21, 30a, 720, 451, 223, 126, 19b, 25 and S-miR-16) were validated to be differentially expressed among the patients in the validation set (Supplementary Table A2 ). These 10 miRNAs were not significantly associated with clinical or molecular characteristics at diagnosis (Supplementary Table A3 ). One exception was for chromosome 13q14 deletion (Del13), which was more frequently found in patients with low S-miR-16 (62 vs 38%, P ¼ 0.003) and S-miR-19b (64 vs 41%, P ¼ 0.01) level (Supplementary Figure A3) . In addition, some of the continuous miRNA levels were significantly correlated with age, hemoglobin and creatinine (Supplementary Table A3 ); however, these were weak associations (|r|o0.22) and scatter-plots reflected weak, if any, relationships with these markers (Supplementary Figure A4) .
To assess prognostic impact, miRNA levels were evaluated as continuous variables. Of the 10 miRNAs, only S-miR-25 was significantly associated with both PFS (P ¼ 0.034) and OS (P ¼ 0.0005) in the univariate setting; S-miR-16 and S-miR30a were only associated with OS (P ¼ 0.008 and P ¼ 0.016, respectively). Patients with higher levels of S-miR-25 (hazard ratio (HR) 0.81; P ¼ 0.0005), S-miR-16 (HR 0.87; P ¼ 0.008) and S-miR-30a (HR 0.86, P ¼ 0.016) had longer OS than those with lower expression of these miRNAs (Table 1) . Only S-miR-25 was significantly associated with PFS duration, where higher S-miR-25 expression was associated with better PFS duration (HR ¼ 0.92; P ¼ 0.034).
A borderline significance for PFS and OS was also seen with S-miR-720, but was not statistically significant in multivariable models.
There was a statistically significant relationship between the presence of deletion 17 on fluorescent in-situ hybridization and both PFS (HR 2.12, P ¼ 0.005) and OS (HR 2.13, P ¼ 0.02). We noted that serum creatinine was highly significant for OS in the univariate setting (P ¼ 0.008). We converted serum creatinine levels to the more clinically meaningful estimated glomerular filtration rate (GFR) using the modification of diet in renal disease equation and thus adjusting for age, gender and race. GFR was not significantly associated with OS (P ¼ 0.15). Of interest, univariate analyses for OS showed a strong gender effect (HR 1.8, P ¼ 0.014), where women had a survival advantage over men in this cohort. However, upon further evaluation, we uncovered that there was also a very significant relationship between gender and serum creatinine levels (Po0.0001). This multicollinearity adds complexity to model building; despite this collinearity, both gender and serum creatinine were included in the multivariable model. Although not as 'normalized' as the GFR measure, we did not want to miss an effect of serum creatinine on OS in these patients.
To assess the independent prognostic impact of the miRNAs on PFS and OS duration, we evaluated several continuous serum miRNA markers in multivariable models that also adjusted for clinical and molecular factors of interest. When we evaluated S-miR-25 and S-miR-720 in relation to PFS when adjusting for the other identified significant factors (treatment arm, ISS stage and del17), it was no longer significant for PFS (P ¼ 0.80). While not significant, S-miR-720 did maintain at least borderline significance for PFS (P ¼ 0.077).
In looking at OS, both S-miR-16 and S-miR-25 were each significantly associated with OS in the univariate setting. However, these two miRNA markers were also highly correlated (r ¼ 0.75; Po0.00001); therefore, we carried forward only S-miR-25 to the multivariable model since it had a greater observed effect and proved to provide a better fit in the models than when S-miR-16 was included. miR-25 was also significantly correlated with miR-30a and miR-720 (Supplementary Table A5 ), but these relationships were not as pronounced. To assess and identify a stable model, we evaluated the models with and without these correlated miRNA markers. Even when we included these additional miRNA markers in the model in addition to the clinical In the multivariable analyses, the Cox regression models were stratified on treatment arm to accommodate any inherent differences in PFS or OS attributable to treatment arm. High positive correlation and issues of strong multicollinearity between miR-25 and miR-16 necessitated only including miR-25 in the model, which was the stronger of the two (r ¼ 0.75, Po0.000001).
d Only failed proportional hazards assumption for OS, but not for PFS.
Letters to the Editor and molecular markers, S-miR-25 retained its significance as a prognostic factor for OS whereas the others did not (Table 1) .
Overall, multivariable models for PFS and OS showed that serum miRNA markers had a significant or at least borderline significant role in determining prognosis. This association was more pronounced when looking at OS, where S-miR-25 remained a significant and relevant factor (P ¼ 0.013) even when adjusting for Del17, Del13, ISS stage, treatment arm, and creatinine and gender ( Table 1 ). The multivariable model for PFS had fewer significant prognostic factors overall, although S-miR-720 still retained at least borderline significance (P ¼ 0.077) even when ISS stage and Del17 were included in the model ( Table 1 ). The impact of S-miR-25 on OS can be readily seen when these levels are dichotomized as high vs low (using a median cutpoint from S-miR-25 levels of healthy normals; HR ¼ 1.66, P ¼ 0.029, Figure 1c) .
In this analysis we found that gender and creatinine were both significant in the univariate setting. While the importance of gender has been rarely reported, 10 we discovered that creatinine and gender were collinear, and that modification of diet in renal disease, which depends on both gender and creatinine, was not an adequate composite variable. Creatinine is also a biomarker of more than renal function in this elderly population, varying by age, gender and weight, and often reflects muscle mass. 11 Circulating miRNAs in MM are poorly understood. Their origin (cancer or normal cell), transit (actively secreted or derived at the time of apoptosis) and most influential location (within PBMCs, extracellular vesicles, or free floating) are all unknown. One report of circulating miRNA in MM identified let-7e and miR-744 as critical to differentiate from normal as well as correlate with overall survival, but this was based on a discovery set of just 13 patients. 12 A study of PBMCs from only 5 MM patients found numerous differences compared to 5 healthy controls, 13 but the small sample size limits generalizability.
We compared intracellular miR-16 and -25 expression in 32 paired samples of serum and PCs obtained patients with a new myeloma diagnosis, but there was no correlation, suggesting that circulating S-miR-16 and S-miR-25 do not reflect the miRNA content of myeloma cells in the marrow. By studying the biological significance of circulating miRNAs we found that miR-25 and miR-16 are encapsulated in extracellular vesicles but these miRNAs do not regulate their target genes post-transcriptionally, suggesting a different mechanism of regulation.
14 Additional work will be required to elucidate the mechanism of action of miR-25 and miR-16 in the extracellular compartment.
In conclusion, we show that circulating miR-16 and miR-25 are independent prognosticators in newly diagnosed MM of OS more so than PFS. We aim to validate these biomarkers in order to use them in combination with the ISS to better risk stratify MM patients.
Impact of chemotherapy delay on short-and long-term survival in younger and older AML patients: a Danish population-based cohort study In recent decades, new strategies and molecularly targeted approaches have been developed to improve treatment in acute myeloid leukemia (AML) patients. To direct therapy, results of conventional cytogenetic and molecular mutation analysis are required. 1 Results can be ready in 72 h, but are generally not available until after 5 days. A relevant question is whether the outcome is affected if intensive chemotherapy awaits results. Only two studies exist on this topic. In an observational US study of 1317 AML patients, delaying treatment beyond 5 days resulted in inferior complete remission (CR) rates and overall survival in younger patients, but not in patients X60 years. 2 As a consequence, LeukemiaNet recommends treatment initiation before day 5 in younger patients. 3 In a French single-center study of 599 patients, no association was found of treatment delays above 5 days compared with patients with a time to treatment initiation (TTT) below 5 days in terms of early death, CR rates and long-term survival. 4 The two studies have important limitations, and the results may not be generalizable to other patients. 5 We designed a national population-based cohort study to investigate the effect of TTT on CR rates and overall survival (30-day and 31-day-3-yearsurvival) in AML patients treated with curative intent in Denmark during 2000-2012. We used the Danish National Acute Leukemia Registry to identify all non-promyelocytic AML patients. The registry covers all AML patients diagnosed in Denmark, and it prospectively collects high-quality demographic, clinical, treatment and outcome data. 6 Information on comorbidity was obtained through the Danish National Registry of Patients. 7 Information on all-cause mortality was obtained from the Civil Registration System. 8 We defined date of diagnosis as the date of first diagnostic bone marrow examination and TTT as the time from diagnosis until the initiation of intensive chemotherapy. Curative treatment intent was defined as allocation to a multiagent remission induction chemotherapy. Information on exposure was grouped into five categories. Patients treated on the day of diagnosis were expected to differ from patients treated later and were kept in a separate category. Factors associated with TTT X5 days and the chance of achieving CR according to TTT were assessed using logistic regression. Overall survival was calculated as the time from diagnosis until death or end of follow-up (18 July 2013). We used Cox proportional hazards regression analysis and restricted cubic splines to assess the influence of TTT on survival. 9 We analyzed data at the time of initiated chemotherapy in an intention-to-treat manner and used the date of chemotherapy as a time-dependent covariate. 10 All survival analyses were stratified by age (o60 years or X60 years), presence of AML secondary to myelodysplastic syndrome or myeloproliferative neoplasias (sAML) or treatment-related AML (tAML) and white blood cells (WBC) (o30 Â 10 9 /l and X30 Â 10 9 /l). All estimates were adjusted for potential prognostic factors, provided with corresponding 95% confidence intervals (CIs) and with TTT ¼ 3-4 days as a reference (detailed in Supplementary Methods).
The study population consisted of 1388 patients (74 patients with TTT 428 days were excluded). Eleven patients (0.8%) died before treatment initiation. The characteristics of the patients included in the study by TTT and age are presented in Supplementary Table S1 . The median TTT was 3 days (interquartile range (IQR) 1-7) and 90% were treated within 13 days. The median TTT was shorter in young patients (3 days (IQR 1-6) vs 4 days (IQR 2-8) in patients X60 years). The median follow-up for all patients was 500 days (range 0-4915). The median TTT did not vary by calendar year or weekday, by inclusion into clinical trials or allogeneic transplantation status, but varied from 2.5 to 5 days between departments. Male gender, presence of comorbidity, sAML/tAML and low WBC predicted longer TTT in younger patients. In patients X60 years, a TTT 45 days was associated with a low WBC and the presence of sAML/tAML (Supplementary Table S2 ). In multivariate analysis, TTT 45 days was not adversely related to CR (Supplementary Table S3 ).
Crude estimates of overall survival according to TTT are shown in Supplementary Figure S1 . Table 1 presents crude and adjusted 0-30-day and 31-day-to-3-year mortality rates (MRs), overall, stratified by age and sAML/tAML. In younger patients and patients X60 years, the adjusted 0-30-day MR did not increase with longer TTT. The association between TTT as a continuous variable and 31-day-to-3-year mortality is described in Figure 1 . The adjusted 31-day-to-3-year MR for all patients combined and for patients X60 years showed an almost U-shaped relation with the lowest MR found in patients with TTT ¼ 3-4 days. In younger patients, only a TTT X10 days was associated with an increased MR (1.57, 95% CI (1.05-2.35)). In patients X60 years, we found a clear association between longer TTT and inferior survival beyond 5 days (adjusted MRs were 1.50, 95% CI (1.07-2.12) and 2.03, 95% CI (1.41-2.92) for TTT ¼ 5-9 days and X9 days, respectively). In de novo patients, TTT X10 days was associated with a worse Accepted article preview online 12 May 2014; advance online publication, 6 June 2014
